2028 年癌症疫苗市场预测——按产品类型、技术、应用、最终用户和地区进行的全球分析

根据Stratistics MRC，2022年全球癌症疫苗市场规模将达到75亿美元，预测期内以16.7%的复合年增长率增长，2028年将达到189.5亿美元，预计将达到美元。

癌症疫苗是被视为生物反应调节剂的药物。 这种生物反应调节剂通过提高人体免疫系统抗癌能力发挥作用。 有两种类型的癌症疫苗：治疗性和预防性。 预防性癌症疫苗用于预防健康人的癌症。 另一方面，癌症患者接受治疗性癌症疫苗以增强免疫力来对抗癌症。 从儿童到成人，癌症疫苗都可以通过静脉滴注进行接种。

据世界癌症研究基金会（WCRF）统计，2020年全球约有1810万癌症患者，其中男性930万，女性880万。

市场动态：

驱动程序

扩大主要市场参与者之间的战略合作伙伴关係

这个市场的特点是默克公司和葛兰素史克公司等行业参与者非常关注新型疫苗的推出。 然而，缺乏产品批准和新疫苗管道中治疗适应症的不平衡引发了人们对巨大市场缺口的担忧。 此外，致力于开发新型癌症疫苗的中小型生物技术公司和学术机构正在努力获得资金和投资。 因此，正在采用鼓励合作的新商业模式来进入国际市场，并将尖端的新产品推向市场。 因此，许多从事预防和治疗疫苗研发的中型免疫治疗公司现在都与业内知名公司合作，进行临床试验以评估疫苗的安全性和有效性。

约束

因个性化医疗的进步而限制使用癌症疫苗

癌症是世界上主要的死亡原因之一，是一种复杂且异质性强的疾病。 治疗性癌症疫苗针对的是癌细胞而不是疾病的根本原因，而预防性癌症疫苗则致力于增强人体对疾病的自然防御能力。 此外，这些疫苗是一种免疫疗法，只有少数癌症类□□型获得了全球产品批准。 一些癌症类型（结直肠癌、乳腺癌、非霍奇金淋巴瘤）根据分子亚型进一步细分。 此外，根据癌症的部位和阶段，即使在同一肿瘤内，特定标誌物的表达方式也不同。 除了癌症疫苗，还需要更精确的治疗来改善这些癌症的预后。 一种新的肿瘤预防和治疗方法是个性化或精准医疗。 有可能针对肿瘤中的促癌因子并以影响其环境的方式改变治疗。

机会

扩大癌症疫苗的临床试验

PDAC（胰腺导管腺癌）是一种常见的胰腺癌，目前尚无治愈方法。 BioNTech 开发的 PDAC 疫苗的 1 期临床试验数据已经发布。 由 BioNTech 开发的 mRNA 疫苗用于将新抗原遗传密码传递给患者的细胞。 该代码告诉细胞产生新抗原，即癌细胞产生的蛋白质。 这些蛋白质用于帮助免疫系统直接攻击肿瘤。

威胁

监管审批时间长，开发成本高

由于开发癌症疫苗的成本高且製造疫苗所需的时间长，预计在预测期内市场发展将受到限制。 此外，在即将推出的疫苗管线中，缺乏产品批准和治疗适应症的不平衡威胁着市场的巨大缺口。

COVID-19 的影响：

2020 年 1 月 30 日，世界卫生组织 (WHO) 宣布 COVID-19 疫情为全球关注的突发公共卫生事件。 全球共有 210 个国家/地区受到 COVID-19 的影响。 随着几个受 COVID-19 影响的国家关闭，以及在 COVID-19 大流行之后生病的医护人员增加，导致短缺，製造和销售癌症疫苗的公司被迫将影响降至最低

Clairvacs 细分市场预计将成为预测期内最大的细分市场

CreaVax 预计将在预测期内显着扩张。 一种基于自体树突状细胞的癌症疫苗，使用患者的外周血单核细胞 (PBMC) 在用肿瘤裂解物和 KLH 致敏后成熟为树突状细胞（匙孔血蓝蛋白）。 Creagene 推出了 Creavax，一种治疗肾细胞癌的疫苗。 CreaVax 对肝细胞癌的疗效目前正在 III 期临床试验中进行研究。

预计成人疫苗部分在预测期内的复合年增长率最高

成人疫苗细分市场占据了最大的市场份额。 此外，世界各地的许多研究人员正在进行深入研究，以开发有效的候选疫苗，以实现潜在的治疗策略。 例如，2022 年 3 月，马里兰州的 Northwest Biotherapeutics 将在其位于英国索斯顿的新製造工厂推出第一种具有先进疗法的个性化树突状细胞药物，用于治疗胶质母细胞瘤病例。我们将宣布，我们将开始出于同情的原因生产癌症疫苗。

市场份额最高的地区

北美的收入份额最高。 在预测期内推动市场的因素包括癌症发病率上升、研究支出增加、市场进入者增加临床试验以及癌症疫苗的监管批准。 例如，美国癌症协会预测，2021 年美国将有 608,570 例癌症死亡和 190 万例新癌症病例。 与此同时，预计到 2022 年将有近 190 万美国人被诊断出患有癌症。 乳腺癌将成为 2018 年最常见的癌症诊断，估计影响 287,850 名女性和 2,710 名男性。 前列腺癌是男性最常见的癌症诊断，也是第二大最常见的癌症诊断。

复合年增长率最高的地区：

欧洲市场预计将显着增长。 这是由癌症疫苗需求增加、癌症患病率上升、欧洲癌症协会和该地区新兴市场参与者对研究的支持增加等因素推动的。这被认为是由于其对疫苗市场的积极影响.

主要发展：

2022 年 6 月，生物技术公司 Treos Bio Limited 宣布了 Polypepi 1018 与 F. Hoffmann-La Roche AG 的 pd-l1 抑製剂联合用于治疗转移性结直肠癌的第 2 期临床试验。宣布试验中的第一位患者已经服药了。

2020年10月，处于临床阶段的生物製药公司Vaccibody AS与罗氏集团成员Genentech合作，开髮用于治疗癌症的基于DNA的个性化新抗原疫苗（DNA癌症疫苗）。宣布它已经签订了一项全球许可和合作协议，用于开发和商业化

2020 年 6 月，UbiVac, Inc. 和 Bristol-Myers Squibb 公布了 UbiVac 的在研产品 DPV-001 联合免疫疗法治疗晚期三阴性乳腺癌的安全性、耐受性和初步结果。宣布建立临床试验合作伙伴关係以评估它的功效。

这份报告提供了什么

• 区域和国家级细分市场的市场份额评估
• 向新进入者提出战略建议
• 2020、2021、2022、2025 和 2028 年的综合市场数据
• 市场趋势（驱动因素、制约因素、机会、威胁、挑战、投资机会、建议）
• 根据市场预测在关键业务领域提出战略建议
• 竞争格局映射关键共同趋势。
• 公司简介，包括详细的战略、财务状况和近期发展
• 映射最新技术进步的供应链趋势

免费定制优惠：

购买此报告的客户将获得以下免费定制选项之一：

• 公司简介
  • 其他市场参与者的综合概况（最多 3 家公司）
  • 主要参与者的 SWOT 分析（最多 3 家公司）
• 区域细分
  • 根据客户的要求对主要国家/地区的市场估计/预测/复合年增长率（注意：基于可行性检查）。
• 竞争基准
  • 根据产品组合、区域影响力和战略联盟对主要参与者进行基准测试

内容

第 1 章执行摘要

第二章前言

• 概览
• 利益相关者
• 调查范围
• 调查方法
  • 数据挖掘
  • 数据分析
  • 数据验证
  • 研究方法
• 调查来源
  • 主要研究来源
  • 二级研究来源
  • 假设

第三章市场趋势分析

• 司机
• 约束因素
• 机会
• 威胁
• 产品分析
• 技术分析
• 应用分析
• 最终用户分析
• 新兴市场
• COVID-19 的影响

第 4 章波特五力分析

• 供应商的议价能力
• 买家的议价能力
• 替代品的威胁
• 新进入者的威胁
• 竞争公司之间的敌对关係

第 5 章全球癌症疫苗市场：按产品类型分类

• 癌症预防疫苗
• 治疗性癌症疫苗

第 6 章全球癌症疫苗市场：按技术分类

• 树突状细胞 (DC) 癌症疫苗
• 重组癌症疫苗
• 全细胞癌疫苗
• 抗原/辅助癌症疫苗
• 病毒载体和 DNA 癌症疫苗
• 亚单位疫苗
• 结合疫苗
• 灭活□□疫苗
• 减毒活疫苗
• 其他技术

第 7 章全球癌症疫苗市场：按应用

• 前列腺癌
• 宫颈癌
• 其他用途

第 8 章全球癌症疫苗市场：按最终用户分类

• 儿科
• 成人
• 其他最终用户

第 9 章全球癌症疫苗市场：按地区

• 北美
  • 美国
  • 加拿大
  • 墨西哥
• 欧洲
  • 德国
  • 英国
  • 意大利
  • 法国
  • 西班牙
  • 其他欧洲
• 亚太地区
  • 日本
  • 中国
  • 印度
  • 澳大利亚
  • 新西兰
  • 韩国
  • 其他亚太地区
• 南美洲
  • 阿根廷
  • 巴西
  • 智利
  • 其他南美洲
• 中东和非洲
  • 沙特阿拉伯
  • 阿拉伯联合酋长国
  • 卡塔尔
  • 南非
  • 其他中东和非洲地区

第10章主要发展

• 合同、伙伴关係、协作和合资企业
• 收购与合併
• 新产品发布
• 业务扩展
• 其他关键策略

第11章公司简介

• Aduro Biotech Inc.
• Advaxis Inc.
• Amgen Inc.
• Argos Therapeutics
• Astellas Pharma Inc.
• Astrazeneca Plc.
• Batavia Bioservices,
• Bristol-Myers Squibb Company
• Csl Limited
• Dandrit Biotech
• Dynavax Technologies Corporation
• Generex Biotechnology Corporation
• Immunocellular Therapeutics, Ltd
• Merck & Co., Inc.
• Sanpower Corporation
• Sanpower Group Co. Ltd.
• Vaccinogen, Inc.

According to Stratistics MRC, the Global Cancer Vaccines Market is accounted for $7.50 billion in 2022 and is expected to reach $18.95 billion by 2028 growing at a CAGR of 16.7% during the forecast period. Cancer vaccines are drugs that are thought of as biological response modifiers. These biological response modifiers work by boosting the body's immune system's capacity to combat cancer. There are two different kinds of cancer vaccines: therapeutic and preventative. In order to prevent cancer in healthy individuals, preventive cancer vaccines are used. In order to boost their immune systems ability to combat the disease, cancer patients receive therapeutic cancer vaccines. Children and adults alike can receive cancer vaccines intravenously .

According to statistics published by the World Cancer Research Fund (WCRF), there were about 18.1 million cancer cases worldwide in 2020, of which 9.3 million were males and 8.8 million females.

Market Dynamics:

Driver:

Growing strategic partnerships among major market players

The market is characterized by a significant focus on the introduction of novel vaccines by industry players like Merck & Co., Inc., GSK plc, and others. However, a sizable market gap is feared due to a lack of product approvals and an imbalance of therapeutic indications in the pipeline for new vaccines. Additionally, small and mid-size biotech businesses as well as academic institutions working to develop novel cancer vaccines are having trouble finding funding and investments. Therefore, new business models that encourage collaboration are being adopted so that these players can access international markets and provide the market with cutting-edge new products. As a result, a number of mid-sized immunotherapy players involved in the research and development of prophylactic and therapeutic vaccines are now working with well-known companies in the industry to carry out clinical trials to gauge the safety and effectiveness of vaccines.

Restraint:

Limiting the use of cancer vaccines with personalized medicine advances

Cancer, one of the leading causes of death worldwide, is a complex and heterogeneous disease. Therapeutic cancer vaccines target the cancer cells rather than the disease's underlying cause, whereas preventive cancer vaccines work to bolster the body's natural defenses against the disease. Additionally, these vaccines are a form of immunotherapy that only has a small number of cancer types for which they have received global product approval. Based on their molecular subtypes, some cancer types (colon, breast, and non-Hodgkin's lymphoma) have even more detailed classifications. Additionally, the location or stage of the cancer affects how certain markers are expressed within the same tumor. In order to improve the prognosis for these cancer types, more precise treatment methods are required in addition to cancer vaccines. A new approach to prevention and treatment in oncology is personalized or precision medicine. It may alter treatment in ways that target the tumor's oncogenic drivers and influence its environment.

Opportunity:

The expansion of cancer vaccine clinical trials

PDAC, or pancreatic ductal adenocarcinoma, is a common form of pancreatic cancer for which there are no curative therapies. Data from the first phase of a clinical trial for BioNTech's PDAC vaccine against PDAC was made public. The mRNA vaccination developed by BioNTech is used to deliver the genetic code for the neoantigen to the patient's cells. The code instructs the cells to produce the neoantigens, proteins created by cancer cells. These proteins are produced to help the immune system attack the tumor directly.

Threat:

Lengthy regulatory approvals and high developing cost

Market growth is anticipated to be constrained during the forecast period due to the high cost of developing cancer vaccines and the prolonged time required for vaccine manufacturing. Additionally, a sizable market gap is threatened by a lack of product approvals and an imbalance of therapeutic indications in the pipeline of upcoming vaccines.

COVID-19 Impact:

On January 30, 2020, the World Health Organization (WHO) declared the COVID-19 outbreak a public health emergency of global concern. A total of 210 countries around the world have been impacted by COVID-19. Due to closures in several COVID-19-affected countries and an increase in the number of sick healthcare workers following the COVID-19 pandemic, which resulted in a shortage, companies that manufacture and distribute cancer vaccines have only been minimally impacted by COVID-19.

The creavax segment is expected to be the largest during the forecast period

CreaVax is expected to expand significantly during the forecast period. The patient's peripheral blood mononuclear cells (PBMC) are used to make the autologous dendritic cell-based cancer vaccine, which is sensitized with tumor lysate and KLH before maturing into dendritic cells (Keyhole Limpet Hemocyanin). Creagene released Creavax, a therapeutic vaccine for renal cell carcinoma. The effectiveness of CreaVax in the treatment of hepatocellular carcinoma is currently being studied in a Phase III clinical trial.

The adult vaccines segment is expected to have the highest CAGR during the forecast period

The adult vaccine market segment had the largest market share. Additionally, a large number of researchers around the world are conducting in-depth research to develop efficient vaccine candidates to realize potential therapeutic strategies. For instance, Northwest Biotherapeutics of Maryland will announce in March 2022 the start of production of the first personalized dendritic cell-based cancer vaccine at its new production facility in Sawston, UK, using advanced therapy medicinal products for the treatment of a glioblastoma case on compassionate grounds.

Region with highest share:

The largest revenue share came from North America. The factors driving the market during the forecast period include the rising incidence of cancer, rising research expenditures, an increase in clinical trials by industry participants, and regulatory approvals for cancer vaccines. For instance, the American Cancer Society predicts that in 2021 there will be 608,570 cancer deaths in the United States and an estimated 1.9 million new cancer cases. In contrast, the number of Americans who will receive a cancer diagnosis in 2022 will be close to 1.9 million. Breast cancer will be the most common cancer diagnosis in 2018, affecting an estimated 287,850 women and 2,710 men. The most frequent cancer diagnosis in men and the second most frequent overall is prostate cancer.

Region with highest CAGR:

Europe's market is expected to grow significantly. This can be attributed to factors such as the rising demand for cancer vaccines, the rising incidence of cancer, the increase in support for research studies from cancer societies across Europe, and emerging market players in the area, all of which have a positive impact on the market for dendritic cell cancer vaccines.

Key players in the market:

Some of the key players in Cancer Vaccines market include Aduro Biotech Inc., Advaxis Inc., Amgen Inc., Argos Therapeutics, Astellas Pharma Inc., Astrazeneca Plc., Batavia Bioservices, Bristol-Myers Squibb Company, Csl Limited, Dandrit Biotech, Dynavax Technologies Corporation, Generex Biotechnology Corporation, Immunocellular Therapeutics, Ltd, Merck & Co., Inc., Sanpower Corporation, Sanpower Group Co. Ltd. And Vaccinogen, Inc.

Key Developments:

In June 2022, Treos Bio Limited, a biotechnology company, announced the first patient dosed in a phase 2 trial of polypepi1018 in combination with pd-l1-inhibitor manufactured by F. Hoffmann-La Roche AG for the treatment of metastatic colorectal cancer.

In October 2020, Vaccibody AS, a clinical-stage biopharmaceutical company, announced its worldwide license and collaboration agreement with Genentech, Inc., a member of the Roche Group, for the development and commercialization of DNA-based individualized neoantigen vaccines (DNA cancer vaccines) for the treatment of cancers.

In June 2020, UbiVac, Inc. announced a clinical trial collaboration with Bristol Myers Squibb to evaluate the safety, tolerability, and preliminary efficacy of UbiVac's investigational product, DPV-001, in combination with Immunotherapy for Advanced Triple Negative Breast Cancer.

Product Types Covered:

• Preventive Cancer Vaccines
• Therapeutic Cancer Vaccines

Technologies Covered:

• Dendritic Cells (DC) Cancer Vaccines
• Recombinant Cancer Vaccines
• Whole-cell Cancer Vaccines
• Antigen/Adjuvant Cancer Vaccines
• Viral Vector & DNA Cancer Vaccines
• Subunit Vaccines
• Conjugate Vaccines
• Inactivated Vaccines
• Live Attenuated Vaccines
• Other Technologies

Applications Covered:

• Prostate Cancer
• Cervical Cancer
• Other Applications

End Users Covered:

• Pediatrics
• Adults
• Other End users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2020, 2021, 2022, 2025, and 2028
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Product Analysis
• 3.7 Technology Analysis
• 3.8 Application Analysis
• 3.9 End User Analysis
• 3.10 Emerging Markets
• 3.11 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Cancer Vaccines Market, By Product Type

• 5.1 Introduction
• 5.2 Preventive Cancer Vaccines
• 5.3 Therapeutic Cancer Vaccines

6 Global Cancer Vaccines Market, By Technology

• 6.1 Introduction
• 6.2 Dendritic Cells (DC) Cancer Vaccines
• 6.3 Recombinant Cancer Vaccines
• 6.4 Whole-cell Cancer Vaccines
• 6.5 Antigen/Adjuvant Cancer Vaccines
• 6.6 Viral Vector & DNA Cancer Vaccines
• 6.7 Subunit Vaccines
• 6.8 Conjugate Vaccines
• 6.9 Inactivated Vaccines
• 6.10 Live Attenuated Vaccines
• 6.11 Other Technologies

7 Global Cancer Vaccines Market, By Application

• 7.1 Introduction
• 7.2 Prostate Cancer
• 7.3 Cervical Cancer
• 7.4 Other Applications

8 Global Cancer Vaccines Market, By End User

• 8.1 Introduction
• 8.2 Pediatrics
• 8.3 Adults
• 8.4 Other End Users

9 Global Cancer Vaccines Market, By Geography

• 9.1 Introduction
• 9.2 North America
  • 9.2.1 US
  • 9.2.2 Canada
  • 9.2.3 Mexico
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 Italy
  • 9.3.4 France
  • 9.3.5 Spain
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 New Zealand
  • 9.4.6 South Korea
  • 9.4.7 Rest of Asia Pacific
• 9.5 South America
  • 9.5.1 Argentina
  • 9.5.2 Brazil
  • 9.5.3 Chile
  • 9.5.4 Rest of South America
• 9.6 Middle East & Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 UAE
  • 9.6.3 Qatar
  • 9.6.4 South Africa
  • 9.6.5 Rest of Middle East & Africa

10 Key Developments

• 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 10.2 Acquisitions & Mergers
• 10.3 New Product Launch
• 10.4 Expansions
• 10.5 Other Key Strategies

11 Company Profiling

• 11.1 Aduro Biotech Inc.
• 11.2 Advaxis Inc.
• 11.3 Amgen Inc.
• 11.4 Argos Therapeutics
• 11.5 Astellas Pharma Inc.
• 11.6 Astrazeneca Plc.
• 11.7 Batavia Bioservices,
• 11.8 Bristol-Myers Squibb Company
• 11.9 Csl Limited
• 11.10 Dandrit Biotech
• 11.11 Dynavax Technologies Corporation
• 11.12 Generex Biotechnology Corporation
• 11.13 Immunocellular Therapeutics, Ltd
• 11.14 Merck & Co., Inc.
• 11.15 Sanpower Corporation
• 11.16 Sanpower Group Co. Ltd.
• 11.17 Vaccinogen, Inc.

List of Tables

• Table 1 Global Cancer Vaccines Market Outlook, By Region (2020-2028) ($MN)
• Table 2 Global Cancer Vaccines Market Outlook, By Product Type (2020-2028) ($MN)
• Table 3 Global Cancer Vaccines Market Outlook, By Preventive Cancer Vaccines (2020-2028) ($MN)
• Table 4 Global Cancer Vaccines Market Outlook, By Therapeutic Cancer Vaccines (2020-2028) ($MN)
• Table 5 Global Cancer Vaccines Market Outlook, By Technology (2020-2028) ($MN)
• Table 6 Global Cancer Vaccines Market Outlook, By Dendritic Cells (DC) Cancer Vaccines (2020-2028) ($MN)
• Table 7 Global Cancer Vaccines Market Outlook, By Recombinant Cancer Vaccines (2020-2028) ($MN)
• Table 8 Global Cancer Vaccines Market Outlook, By Whole-cell Cancer Vaccines (2020-2028) ($MN)
• Table 9 Global Cancer Vaccines Market Outlook, By Antigen/Adjuvant Cancer Vaccines (2020-2028) ($MN)
• Table 10 Global Cancer Vaccines Market Outlook, By Viral Vector & DNA Cancer Vaccines (2020-2028) ($MN)
• Table 11 Global Cancer Vaccines Market Outlook, By Subunit Vaccines (2020-2028) ($MN)
• Table 12 Global Cancer Vaccines Market Outlook, By Conjugate Vaccines (2020-2028) ($MN)
• Table 13 Global Cancer Vaccines Market Outlook, By Inactivated Vaccines (2020-2028) ($MN)
• Table 14 Global Cancer Vaccines Market Outlook, By Live Attenuated Vaccines (2020-2028) ($MN)
• Table 15 Global Cancer Vaccines Market Outlook, By Other Technologies (2020-2028) ($MN)
• Table 16 Global Cancer Vaccines Market Outlook, By Application (2020-2028) ($MN)
• Table 17 Global Cancer Vaccines Market Outlook, By Prostate Cancer (2020-2028) ($MN)
• Table 18 Global Cancer Vaccines Market Outlook, By Cervical Cancer (2020-2028) ($MN)
• Table 19 Global Cancer Vaccines Market Outlook, By Other Applications (2020-2028) ($MN)
• Table 20 Global Cancer Vaccines Market Outlook, By End User (2020-2028) ($MN)
• Table 21 Global Cancer Vaccines Market Outlook, By Pediatrics (2020-2028) ($MN)
• Table 22 Global Cancer Vaccines Market Outlook, By Adults (2020-2028) ($MN)
• Table 23 Global Cancer Vaccines Market Outlook, By Other End Users (2020-2028) ($MN)
• Table 24 North America Cancer Vaccines Market Outlook, By Country (2020-2028) ($MN)
• Table 25 North America Cancer Vaccines Market Outlook, By Product Type (2020-2028) ($MN)
• Table 26 North America Cancer Vaccines Market Outlook, By Preventive Cancer Vaccines (2020-2028) ($MN)
• Table 27 North America Cancer Vaccines Market Outlook, By Therapeutic Cancer Vaccines (2020-2028) ($MN)
• Table 28 North America Cancer Vaccines Market Outlook, By Technology (2020-2028) ($MN)
• Table 29 North America Cancer Vaccines Market Outlook, By Dendritic Cells (DC) Cancer Vaccines (2020-2028) ($MN)
• Table 30 North America Cancer Vaccines Market Outlook, By Recombinant Cancer Vaccines (2020-2028) ($MN)
• Table 31 North America Cancer Vaccines Market Outlook, By Whole-cell Cancer Vaccines (2020-2028) ($MN)
• Table 32 North America Cancer Vaccines Market Outlook, By Antigen/Adjuvant Cancer Vaccines (2020-2028) ($MN)
• Table 33 North America Cancer Vaccines Market Outlook, By Viral Vector & DNA Cancer Vaccines (2020-2028) ($MN)
• Table 34 North America Cancer Vaccines Market Outlook, By Subunit Vaccines (2020-2028) ($MN)
• Table 35 North America Cancer Vaccines Market Outlook, By Conjugate Vaccines (2020-2028) ($MN)
• Table 36 North America Cancer Vaccines Market Outlook, By Inactivated Vaccines (2020-2028) ($MN)
• Table 37 North America Cancer Vaccines Market Outlook, By Live Attenuated Vaccines (2020-2028) ($MN)
• Table 38 North America Cancer Vaccines Market Outlook, By Other Technologies (2020-2028) ($MN)
• Table 39 North America Cancer Vaccines Market Outlook, By Application (2020-2028) ($MN)
• Table 40 North America Cancer Vaccines Market Outlook, By Prostate Cancer (2020-2028) ($MN)
• Table 41 North America Cancer Vaccines Market Outlook, By Cervical Cancer (2020-2028) ($MN)
• Table 42 North America Cancer Vaccines Market Outlook, By Other Applications (2020-2028) ($MN)
• Table 43 North America Cancer Vaccines Market Outlook, By End User (2020-2028) ($MN)
• Table 44 North America Cancer Vaccines Market Outlook, By Pediatrics (2020-2028) ($MN)
• Table 45 North America Cancer Vaccines Market Outlook, By Adults (2020-2028) ($MN)
• Table 46 North America Cancer Vaccines Market Outlook, By Other End Users (2020-2028) ($MN)
• Table 47 Europe Cancer Vaccines Market Outlook, By Country (2020-2028) ($MN)
• Table 48 Europe Cancer Vaccines Market Outlook, By Product Type (2020-2028) ($MN)
• Table 49 Europe Cancer Vaccines Market Outlook, By Preventive Cancer Vaccines (2020-2028) ($MN)
• Table 50 Europe Cancer Vaccines Market Outlook, By Therapeutic Cancer Vaccines (2020-2028) ($MN)
• Table 51 Europe Cancer Vaccines Market Outlook, By Technology (2020-2028) ($MN)
• Table 52 Europe Cancer Vaccines Market Outlook, By Dendritic Cells (DC) Cancer Vaccines (2020-2028) ($MN)
• Table 53 Europe Cancer Vaccines Market Outlook, By Recombinant Cancer Vaccines (2020-2028) ($MN)
• Table 54 Europe Cancer Vaccines Market Outlook, By Whole-cell Cancer Vaccines (2020-2028) ($MN)
• Table 55 Europe Cancer Vaccines Market Outlook, By Antigen/Adjuvant Cancer Vaccines (2020-2028) ($MN)
• Table 56 Europe Cancer Vaccines Market Outlook, By Viral Vector & DNA Cancer Vaccines (2020-2028) ($MN)
• Table 57 Europe Cancer Vaccines Market Outlook, By Subunit Vaccines (2020-2028) ($MN)
• Table 58 Europe Cancer Vaccines Market Outlook, By Conjugate Vaccines (2020-2028) ($MN)
• Table 59 Europe Cancer Vaccines Market Outlook, By Inactivated Vaccines (2020-2028) ($MN)
• Table 60 Europe Cancer Vaccines Market Outlook, By Live Attenuated Vaccines (2020-2028) ($MN)
• Table 61 Europe Cancer Vaccines Market Outlook, By Other Technologies (2020-2028) ($MN)
• Table 62 Europe Cancer Vaccines Market Outlook, By Application (2020-2028) ($MN)
• Table 63 Europe Cancer Vaccines Market Outlook, By Prostate Cancer (2020-2028) ($MN)
• Table 64 Europe Cancer Vaccines Market Outlook, By Cervical Cancer (2020-2028) ($MN)
• Table 65 Europe Cancer Vaccines Market Outlook, By Other Applications (2020-2028) ($MN)
• Table 66 Europe Cancer Vaccines Market Outlook, By End User (2020-2028) ($MN)
• Table 67 Europe Cancer Vaccines Market Outlook, By Pediatrics (2020-2028) ($MN)
• Table 68 Europe Cancer Vaccines Market Outlook, By Adults (2020-2028) ($MN)
• Table 69 Europe Cancer Vaccines Market Outlook, By Other End Users (2020-2028) ($MN)
• Table 70 Asia Pacific Cancer Vaccines Market Outlook, By Country (2020-2028) ($MN)
• Table 71 Asia Pacific Cancer Vaccines Market Outlook, By Product Type (2020-2028) ($MN)
• Table 72 Asia Pacific Cancer Vaccines Market Outlook, By Preventive Cancer Vaccines (2020-2028) ($MN)
• Table 73 Asia Pacific Cancer Vaccines Market Outlook, By Therapeutic Cancer Vaccines (2020-2028) ($MN)
• Table 74 Asia Pacific Cancer Vaccines Market Outlook, By Technology (2020-2028) ($MN)
• Table 75 Asia Pacific Cancer Vaccines Market Outlook, By Dendritic Cells (DC) Cancer Vaccines (2020-2028) ($MN)
• Table 76 Asia Pacific Cancer Vaccines Market Outlook, By Recombinant Cancer Vaccines (2020-2028) ($MN)
• Table 77 Asia Pacific Cancer Vaccines Market Outlook, By Whole-cell Cancer Vaccines (2020-2028) ($MN)
• Table 78 Asia Pacific Cancer Vaccines Market Outlook, By Antigen/Adjuvant Cancer Vaccines (2020-2028) ($MN)
• Table 79 Asia Pacific Cancer Vaccines Market Outlook, By Viral Vector & DNA Cancer Vaccines (2020-2028) ($MN)
• Table 80 Asia Pacific Cancer Vaccines Market Outlook, By Subunit Vaccines (2020-2028) ($MN)
• Table 81 Asia Pacific Cancer Vaccines Market Outlook, By Conjugate Vaccines (2020-2028) ($MN)
• Table 82 Asia Pacific Cancer Vaccines Market Outlook, By Inactivated Vaccines (2020-2028) ($MN)
• Table 83 Asia Pacific Cancer Vaccines Market Outlook, By Live Attenuated Vaccines (2020-2028) ($MN)
• Table 84 Asia Pacific Cancer Vaccines Market Outlook, By Other Technologies (2020-2028) ($MN)
• Table 85 Asia Pacific Cancer Vaccines Market Outlook, By Application (2020-2028) ($MN)
• Table 86 Asia Pacific Cancer Vaccines Market Outlook, By Prostate Cancer (2020-2028) ($MN)
• Table 87 Asia Pacific Cancer Vaccines Market Outlook, By Cervical Cancer (2020-2028) ($MN)
• Table 88 Asia Pacific Cancer Vaccines Market Outlook, By Other Applications (2020-2028) ($MN)
• Table 89 Asia Pacific Cancer Vaccines Market Outlook, By End User (2020-2028) ($MN)
• Table 90 Asia Pacific Cancer Vaccines Market Outlook, By Pediatrics (2020-2028) ($MN)
• Table 91 Asia Pacific Cancer Vaccines Market Outlook, By Adults (2020-2028) ($MN)
• Table 92 Asia Pacific Cancer Vaccines Market Outlook, By Other End Users (2020-2028) ($MN)
• Table 93 South America Cancer Vaccines Market Outlook, By Country (2020-2028) ($MN)
• Table 94 South America Cancer Vaccines Market Outlook, By Product Type (2020-2028) ($MN)
• Table 95 South America Cancer Vaccines Market Outlook, By Preventive Cancer Vaccines (2020-2028) ($MN)
• Table 96 South America Cancer Vaccines Market Outlook, By Therapeutic Cancer Vaccines (2020-2028) ($MN)
• Table 97 South America Cancer Vaccines Market Outlook, By Technology (2020-2028) ($MN)
• Table 98 South America Cancer Vaccines Market Outlook, By Dendritic Cells (DC) Cancer Vaccines (2020-2028) ($MN)
• Table 99 South America Cancer Vaccines Market Outlook, By Recombinant Cancer Vaccines (2020-2028) ($MN)
• Table 100 South America Cancer Vaccines Market Outlook, By Whole-cell Cancer Vaccines (2020-2028) ($MN)
• Table 101 South America Cancer Vaccines Market Outlook, By Antigen/Adjuvant Cancer Vaccines (2020-2028) ($MN)
• Table 102 South America Cancer Vaccines Market Outlook, By Viral Vector & DNA Cancer Vaccines (2020-2028) ($MN)
• Table 103 South America Cancer Vaccines Market Outlook, By Subunit Vaccines (2020-2028) ($MN)
• Table 104 South America Cancer Vaccines Market Outlook, By Conjugate Vaccines (2020-2028) ($MN)
• Table 105 South America Cancer Vaccines Market Outlook, By Inactivated Vaccines (2020-2028) ($MN)
• Table 106 South America Cancer Vaccines Market Outlook, By Live Attenuated Vaccines (2020-2028) ($MN)
• Table 107 South America Cancer Vaccines Market Outlook, By Other Technologies (2020-2028) ($MN)
• Table 108 South America Cancer Vaccines Market Outlook, By Application (2020-2028) ($MN)
• Table 109 South America Cancer Vaccines Market Outlook, By Prostate Cancer (2020-2028) ($MN)
• Table 110 South America Cancer Vaccines Market Outlook, By Cervical Cancer (2020-2028) ($MN)
• Table 111 South America Cancer Vaccines Market Outlook, By Other Applications (2020-2028) ($MN)
• Table 112 South America Cancer Vaccines Market Outlook, By End User (2020-2028) ($MN)
• Table 113 South America Cancer Vaccines Market Outlook, By Pediatrics (2020-2028) ($MN)
• Table 114 South America Cancer Vaccines Market Outlook, By Adults (2020-2028) ($MN)
• Table 115 South America Cancer Vaccines Market Outlook, By Other End Users (2020-2028) ($MN)
• Table 116 Middle East & Africa Cancer Vaccines Market Outlook, By Country (2020-2028) ($MN)
• Table 117 Middle East & Africa Cancer Vaccines Market Outlook, By Product Type (2020-2028) ($MN)
• Table 118 Middle East & Africa Cancer Vaccines Market Outlook, By Preventive Cancer Vaccines (2020-2028) ($MN)
• Table 119 Middle East & Africa Cancer Vaccines Market Outlook, By Therapeutic Cancer Vaccines (2020-2028) ($MN)
• Table 120 Middle East & Africa Cancer Vaccines Market Outlook, By Technology (2020-2028) ($MN)
• Table 121 Middle East & Africa Cancer Vaccines Market Outlook, By Dendritic Cells (DC) Cancer Vaccines (2020-2028) ($MN)
• Table 122 Middle East & Africa Cancer Vaccines Market Outlook, By Recombinant Cancer Vaccines (2020-2028) ($MN)
• Table 123 Middle East & Africa Cancer Vaccines Market Outlook, By Whole-cell Cancer Vaccines (2020-2028) ($MN)
• Table 124 Middle East & Africa Cancer Vaccines Market Outlook, By Antigen/Adjuvant Cancer Vaccines (2020-2028) ($MN)
• Table 125 Middle East & Africa Cancer Vaccines Market Outlook, By Viral Vector & DNA Cancer Vaccines (2020-2028) ($MN)
• Table 126 Middle East & Africa Cancer Vaccines Market Outlook, By Subunit Vaccines (2020-2028) ($MN)
• Table 127 Middle East & Africa Cancer Vaccines Market Outlook, By Conjugate Vaccines (2020-2028) ($MN)
• Table 128 Middle East & Africa Cancer Vaccines Market Outlook, By Inactivated Vaccines (2020-2028) ($MN)
• Table 129 Middle East & Africa Cancer Vaccines Market Outlook, By Live Attenuated Vaccines (2020-2028) ($MN)
• Table 130 Middle East & Africa Cancer Vaccines Market Outlook, By Other Technologies (2020-2028) ($MN)
• Table 131 Middle East & Africa Cancer Vaccines Market Outlook, By Application (2020-2028) ($MN)
• Table 132 Middle East & Africa Cancer Vaccines Market Outlook, By Prostate Cancer (2020-2028) ($MN)
• Table 133 Middle East & Africa Cancer Vaccines Market Outlook, By Cervical Cancer (2020-2028) ($MN)
• Table 134 Middle East & Africa Cancer Vaccines Market Outlook, By Other Applications (2020-2028) ($MN)
• Table 135 Middle East & Africa Cancer Vaccines Market Outlook, By End User (2020-2028) ($MN)
• Table 136 Middle East & Africa Cancer Vaccines Market Outlook, By Pediatrics (2020-2028) ($MN)
• Table 137 Middle East & Africa Cancer Vaccines Market Outlook, By Adults (2020-2028) ($MN)
• Table 138 Middle East & Africa Cancer Vaccines Market Outlook, By Other End Users (2020-2028) ($MN)